ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer

In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.

ovarian cancer
Platinum-resistant ovarian cancer has a mostly poor prognosis • Source: Shutterstock

Simcere Pharmaceutical Group's novel recombinant anti-VEGF antibody suvemcitug has shown a promising overall survival trend in still immature data in platinum-resistant ovarian cancer presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, which could position it well on this benchmark against other current mainstay same-class therapies.

More from ASCO

More from Conferences